GPX4 and cancer: More convincingly, emerging evidence also supported that the loss of GPX4 strengthened the sensitivity of tumor cells to chemotherapy, hormone therapy, radiotherapy, and immunotherapy [172,173,174,175], which, together, reinforced the feasibility of targeting ferroptosis in different cancers [176].